DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMAC · Real-Time Price · USD
4.700
+0.520 (12.44%)
Nov 22, 2024, 4:00 PM EST - Market closed
DiaMedica Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 7.85 | 8.16 | 6.16 | 4.88 | 4.49 | 3.69 | |
| Research & Development | 16.26 | 13.11 | 7.84 | 8.77 | 8.21 | 7.9 | |
| Operating Expenses | 24.11 | 21.27 | 14 | 13.65 | 12.7 | 11.59 | |
| Operating Income | -24.11 | -21.27 | -14 | -13.65 | -12.7 | -11.59 | |
| Interest & Investment Income | 1.93 | 1.93 | 0.35 | - | - | - | |
| Other Non Operating Income (Expenses) | 0.52 | - | - | 0.08 | 0.43 | 0.98 | |
| EBT Excluding Unusual Items | -21.66 | -19.34 | -13.65 | -13.56 | -12.27 | -10.62 | |
| Pretax Income | -21.66 | -19.34 | -13.65 | -13.56 | -12.27 | -10.62 | |
| Income Tax Expense | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Net Income | -21.71 | -19.38 | -13.68 | -13.59 | -12.29 | -10.65 | |
| Net Income to Common | -21.71 | -19.38 | -13.68 | -13.59 | -12.29 | -10.65 | |
| Shares Outstanding (Basic) | 39 | 33 | 26 | 21 | 16 | 12 | |
| Shares Outstanding (Diluted) | 39 | 33 | 26 | 21 | 16 | 12 | |
| Shares Change (YoY) | 32.12% | 23.16% | 27.29% | 32.48% | 30.80% | 54.81% | |
| EPS (Basic) | -0.55 | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | |
| EPS (Diluted) | -0.56 | -0.60 | -0.52 | -0.65 | -0.78 | -0.89 | |
| Free Cash Flow | -19.48 | -18.75 | -11.59 | -12.27 | -9.23 | -9.1 | |
| Free Cash Flow Per Share | -0.50 | -0.58 | -0.44 | -0.59 | -0.59 | -0.76 | |
| EBITDA | -24.07 | -21.24 | -13.98 | -13.62 | -12.68 | -11.57 | |
| D&A For EBITDA | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
| EBIT | -24.11 | -21.27 | -14 | -13.65 | -12.7 | -11.59 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.